Neuralstem Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
19,831.90
22,628.70
20,903.90
21,074.60
15,666.00
4,924.60
Depreciation, Depletion & Amortization
244.70
348.60
345.50
337.50
289.20
185.80
Other Funds
-
426.20
847.10
-
-
2,616.70
Funds from Operations
10,596.10
13,240.60
16,736.50
17,127.50
11,262.30
7,355.50
Changes in Working Capital
4.50
1,534.00
2,195.10
1,511.40
2,153.90
336.90
Net Operating Cash Flow
10,591.60
11,706.70
18,931.70
15,616.10
13,416.20
7,692.40
Capital Expenditures
537.10
556.30
243.60
161.10
94.00
Purchase/Sale of Investments
-
15,007.50
7,490.00
2,517.50
-
Net Investing Cash Flow
537.10
15,563.80
7,246.40
2,356.30
94.00
Issuance/Reduction of Debt, Net
7,368.00
2,107.90
1,271.20
4,380.20
3,745.20
Net Financing Cash Flow
20,524.70
22,944.40
3,887.20
23,738.70
4,990.80
Net Change in Cash
9,402.30
4,327.10
7,802.40
10,478.40
8,520.00
Free Cash Flow
10,717.00
11,914.60
19,107.90
15,714.20
13,427.60
Change in Capital Stock
13,156.70
21,262.70
6,005.50
28,119.00
8,736.00
Exchange Rate Effect
6.20
1.00
4.40
0.50
0.60

About Neuralstem

View Profile
Address
20271 Goldenrod Lane
Germantown Maryland 20876
United States
Employees -
Website http://www.neuralstem.com
Updated 07/08/2019
Neuralstem, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel and proprietary chemical entity screening platform. The company was founded by I.